Health minister: Tdap vaccine now available free for pregnant women at MOH facilities
PUTRAJAYA, May 26 — The Tdap vaccine (for tetanus, diphtheria and pertussis) is being offered free of charge to pregnant women between 28 and 32 weeks of gestation from today, said Minister of Health Datuk Seri Dr Dzulkefly Ahmad.
He added that the Tdap vaccination is being offered at all Ministry of Health (MOH) primary health facilities that provide maternal health services nationwide.
'This vaccine is aimed at providing early protection to newborns, who are susceptible to complications from pertussis (whooping cough) before completing the vaccination schedule.
'International studies have also shown that this vaccine is safe and effective, without increasing any risks to the mother or baby,' he said at the National-Level Immunisation Day celebration held here today.
He said although the MOH does not make it compulsory for pregnant women to take the Tdap vaccine, they are, however, strongly encouraged to do so.
He said that in addition to the vaccine for pregnant women, which is an initiative under its lifelong immunisation strategy, the MOH had also launched the Influenza Immunisation Programme for Senior Citizens on Feb 18 by targeting those aged 60 and above with at least one listed chronic illness.
Dzulkefly said that as of yesterday, a total of 97,355 senior citizens had received the influenza vaccine at MOH facilities.
Meanwhile, he said that the national immunisation policy is regularly reviewed based on scientific evidence and international guidelines and, as such, emphasised that all vaccines used in Malaysia have undergone rigorous efficacy and safety assessments by the National Pharmaceutical Regulatory Agency (NPRA) and are continuously monitored by the MOH.
'There is a growing concern regarding the false dissemination of fake news and information and this undermines public confidence. I understand that some parents are still unsure.
'I urge everyone to always refer to official sources because our decision today will affect the health of future generations,' he said. — Bernama
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
2 hours ago
- Malay Mail
First vape, next cake? The slippery slope of selective bans — Sim Tian Hong
JUNE 10 — The recent calls for a nationwide vape ban have been hogging the headlines. Just recently, Segamat MP R. Yuneswaran urged the Federal government to impose a blanket ban, citing rising healthcare costs and increasing youth vaping rates. Meanwhile, states such as Selangor, Kelantan, Johor, Negeri Sembilan and Terengganu have already moved ahead with bans of their own or are debating similar measures. These moves are driven by understandable public health concerns. No one is questioning the motivations behind such calls. After all, nothing is more important than public health. However, are we approaching this issue in a consistent and coherent way? If we are banning vape to protect public health, why are cigarettes — a product known to cause cancer, heart disease, and countless other illnesses — still legally sold and taxed? According to the Ministry of Health, tobacco use remains one of the most preventable causes of death in Malaysia. Yet, while vape is being banned or restricted in piecemeal fashion, cigarettes remain a fixture in convenience stores nationwide. The recent calls for a nationwide vape ban have been hogging the headlines. — Picture by Raymond Manuel This inconsistency becomes even more troubling when one considers the fragmented nature of the current policy response. Some states are imposing their own bans, others are not. The Federal government has yet to adopt a clear, unified stance. The result is a patchwork of differing rules across the country. This is bound to create confusion for the public, enforcement challenges for authorities, and opportunities for an illicit market to flourish. There is also the risk of setting a questionable policy precedent. If the principle is that we should ban products that can harm public health, where do we draw the line? Should we also move to ban junk food, sugary drinks, or alcohol, all of which contribute to non-communicable diseases and healthcare costs? I am not suggesting that we ignore the risks associated with vaping. But we should be wary of making selective, reactive policy decisions that are not grounded in a consistent framework. Rather than imposing outright bans in an uneven and fragmented way, there is a case for a more balanced and coherent approach. Stronger public education campaigns, tighter regulation of marketing and sales (especially to minors), and consistent enforcement across states may ultimately prove more effective than prohibition alone. Above all, public health policy should be seen as fair, rational, and consistent. A strategy that appears to single out certain products while ignoring others with well-documented harms, risks undermining public trust. It may also distract from the broader effort to build a healthier society. Public health must always come first. But in pursuing that goal, we should avoid the temptation to adopt inconsistent or populist measures that may generate headlines, but not necessarily better outcomes. * This is the personal opinion of the writer or publication and does not necessarily represent the views of Malay Mail.
Free Malaysia Today
3 hours ago
- Free Malaysia Today
Second Australian IVF mix-up shakes clinic and industry
Fertility experts say reports of transferring the wrong embryo are rare. (EPA Images pic) SYDNEY : One of Australia's top IVF providers mistakenly implanted a patient with her own embryo instead of her partner's in a second fertility clinic mix-up, heightening concerns about an industry that did not have much active government oversight until recently. Monash IVF said the error took place on June 5 at a clinic in Melbourne but did not provide further details such as how it learned of the bungle or what the couple planned to do next. The company said it was supporting the couple, who it did not identify. It said the patient's embryo was mistakenly implanted under a treatment plan that called for an embryo from the patient's partner to be transferred. The incident builds on a reputational maelstrom for Monash IVF which was already reeling from an April disclosure that an Australian woman had given birth to a stranger's baby after a fertility doctor accidentally implanted the wrong embryo into a patient in Brisbane in 2023. That mix-up sparked concerns about security protocols at IVF clinics and an industry which is only now in the process of being more regulated. Monash claimed the world's first IVF pregnancy five decades ago and is Australia's second-largest IVF provider, carrying out nearly a quarter of the country's 100,000 assisted reproductive cycles a year, according to industry data. 'This mix-up, the second reported incident at Monash IVF, risks shaking confidence not just in one provider but across the entire fertility sector,' Hilary Bowman-Smart, a researcher and bioethicist at the University of South Australia. Shares of Monash IVF were down 24% by midsession today, against a rising broader market. The stock is just over half its value before the April announcement. 'We had thought the Brisbane clinic embryo transfer error was an isolated incident,' Craig Wong-Pan, an analyst at RBC Capital Markets, said in a client note. 'We believe there is now risk of a greater impact of reputational damage and market share losses to MVF's operations.' Monash IVF had already hired a lawyer to run an independent investigation after the Brisbane incident, and said today it has extended the scope of that investigation. It added that it was installing interim extra verification safeguards to ensure patient confidence. 'Whilst industry-leading electronic witness systems… are being rolled out across Monash IVF, there remains instances and circumstances whereby manual witnessing is required,' the company said. It said it had reported the Melbourne incident to state regulator the Victorian department of health and industry licencing body the reproductive technology accreditation committee (RTAC), part of industry group the Fertility Society of Australia. The health department and RTAC were not immediately available for comment. Reports of transferring the wrong embryo are rare, according to fertility experts, and Monash's Brisbane mix-up was widely reported as the first known case of its kind.
Daily Express
4 hours ago
- Daily Express
Ispire Malaysia says Johor plant operating above board
Published on: Tuesday, June 10, 2025 Published on: Tue, Jun 10, 2025 By: FMT Reporters Text Size: Health minister Dzulkefly Ahmad had said that the Cabinet would decide on the fate of Ispire Malaysia Sdn Bhd's operations in Senai, Johor. (LinkedIn pic) PETALING JAYA: Ispire Malaysia Sdn Bhd today affirmed that its plant in Senai, Johor, which manufactures electronic cigarette devices, is fully compliant with local laws and regulations. In a statement, the firm said it operates under stringent procedures to ensure that all manufacturing activities at its Johor facility are exclusively for export purposes. Advertisement 'To date, Ispire Malaysia exclusively manufactures semi-finished hardware products destined solely for export. 'These products do not contain any nicotine or cannabis – liquid or gel – and thus are not subject to the health ministry's regulations under the Control of Smoking Products for Public Health Act 2024,' it said. It added that the products manufactured in its Johor facility are not marketed, sold, or distributed within Malaysia and not accessible to local consumers. All finished products are exported to regulated international markets such as the US and UK where they are approved for sale by local regulators, the company said. The firm also said that references cited in recent reports were largely drawn from Ispire's official US website and pertained to its business-to-business sales operations in jurisdictions where cannabis and related products are legal. 'These statements do not accurately reflect the operations of Ispire Malaysia, which strictly adheres to all Malaysian laws and regulatory requirements/frameworks,' it said. Health think tank CodeBlue previously reported that Ispire produces nicotine and cannabis-related vaping products, and that its devices are used by clients to fill cartridges with cannabis oils in global markets. The report cited an investor presentation in Las Vegas in April, published on YouTube on May 6, which stated that Ispire produces 'mainly cannabis-related products' in its Malaysian manufacturing facility, which has up to seven production lines. In a statement last week, the health ministry confirmed that the government had issued Ispire an interim nicotine manufacturing licence to produce e-cigarettes with nicotine in its plant in Johor, together with local council approval. However, CodeBlue noted that the ministry's June 2 statement did not mention the plant's production of cannabis vaporisers, which reportedly began in February 2024. Ispire Malaysia today said that any production of nicotine-based products, if initiated, would be strictly for export and subject to formal approval by all relevant government agencies at both federal and state levels. Yesterday, health minister Dzulkefly Ahmad said that the Cabinet would decide on the fate of Ispire's operations in Malaysia. * Follow us on our official WhatsApp channel and Telegram for breaking news alerts and key updates! * Do you have access to the Daily Express e-paper and online exclusive news? Check out subscription plans available. Stay up-to-date by following Daily Express's Telegram channel. Daily Express Malaysia
